Avenue Therapeutics Inc (NASDAQ:ATXI) shares traded -6.99% lower at $0.17 on Wall Street last session.
In accordance with the data, 1 analysts cover Avenue Therapeutics Inc (NASDAQ:ATXI). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $32.00, we find $32.00. Given the previous closing price of $0.19, this indicates a potential upside of 16742.11 percent. ATXI stock price is now -60.59% away from the 50-day moving average and -80.83% away from the 200-day moving average. The market capitalization of the company currently stands at $2.31M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $32.00 as their price target over the next twelve months.
In other news, Fortress Biotech, Inc., 10% Owner bought 418,410 shares of the company’s stock on Sep 08. The stock was bought for $301,255 at an average price of $0.72. Upon completion of the transaction, the 10% Owner now directly owns 1,032,390 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 08, Director ROSENWALD LINDSAY A MD bought 348,675 shares of the business’s stock. A total of $251,046 was incurred on buying the stock at an average price of $0.72. This leaves the insider owning 354,318 shares of the company worth $60234.06. A total of 24.87% of the company’s stock is owned by insiders.
Avenue Therapeutics Inc (NASDAQ: ATXI) opened at $0.3000 on Wednesday. During the past 12 months, Avenue Therapeutics Inc has had a low of $0.17 and a high of $2.35. The fifty day moving average price for ATXI is $0.4426 and a two-hundred day moving average price translates $0.9099 for the stock.
The latest earnings results from Avenue Therapeutics Inc (NASDAQ: ATXI) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at $0.06, beating analysts’ expectations of -$0.26 by 0.32. This compares to -$0.45 EPS in the same period last year. The company reported revenue of $2.07 million for the quarter, compared to $0.66 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 211.92 percent.
Avenue Therapeutics Inc(ATXI) Company Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
